3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Unknown
1
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Urinary Bladder Neoplasms
1
Recurrence
1
Neoplasms
1
Neoplasm Metastasis
1
Mesothelioma, Malignant
1
Colorectal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Hepatocellular
1
Camurati-Engelmann Syndrome
1
Advanced Solid Tumors
1
Interventions
Sorafenib
121
Nivolumab
36
pembrolizumab
32
Bevacizumab
28
lenvatinib
27
Doxorubicin
23
Radiosurgery
21
Radiofrequency Ablation
20
Oxaliplatin
20
Hepatectomy
18
Fluorouracil
15
Capecitabine
15
Magnetic Resonance Spectroscopy
14
atezolizumab
13
Leucovorin
13
Cisplatin
13
Gemcitabine
11
Erlotinib Hydrochloride
11
tislelizumab
9
Sirolimus
9
Radiotherapy
9
Irinotecan
9
Ipilimumab
9
cabozantinib
8
Liver Transplantation
8
regorafenib
7
Ramucirumab
7
Folfox protocol
7
Embolization, Therapeutic
7
sintilimab
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Carcinoma, Hepatocellular
×
ascrinvacumab
×
Clear all
NCT01337050
2015-10-28
Asian Phase I Study Of PF-03446962
Pfizer
Phase 1
Completed
36 enrolled
24 charts